Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 04, 2020 08:00 ET | Source: Salarius Pharmaceuticals

Salarius Announces Allowance of New European Patent Covering Seclidemstat

European Patent Office Satisfied Patent Application Meets All Requirements Salarius’ Global Intellectual Property Estate Includes 22 Issued Patents in the U.S., Europe and 12 Other Jurisdictions ...
March 02, 2020 08:00 ET | Source: Salarius Pharmaceuticals

Salarius Pharmaceuticals to Attend the Oppenheimer Healthcare Conference

HOUSTON, March 02, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today...
February 11, 2020 16:05 ET | Source: Salarius Pharmaceuticals

Salarius Announces Closing of $11.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

HOUSTON, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced...
February 10, 2020 08:00 ET | Source: Salarius Pharmaceuticals

Salarius Pharmaceuticals to Present at the Noble Capital Markets’ 16th Annual Small & Microcap Investor Conference

HOUSTON, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced...
February 07, 2020 08:30 ET | Source: Salarius Pharmaceuticals

Salarius Announces Pricing of $9.6 Million Underwritten Public Offering

HOUSTON, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, today announced the pricing of...
February 05, 2020 08:00 ET | Source: Salarius Pharmaceuticals

Salarius Pharmaceuticals to Present at the BIO CEO & Investor Conference

HOUSTON, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced...
February 04, 2020 08:00 ET | Source: Salarius Pharmaceuticals

Salarius Announces Publication of Scientific Paper Highlighting Potential of Combining Seclidemstat with Checkpoint Inhibitors

Seclidemstat Modulates Tumor Microenvironment to Help Genetically Mutated Cancer Types Overcome Resistance to Checkpoint Inhibitors in Preclinical Study Data Supports Continued Study of Seclidemstat...
December 19, 2019 08:00 ET | Source: Salarius Pharmaceuticals

Salarius Pharmaceuticals to Present at Biotech Showcase 2020

HOUSTON, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, referred...
December 17, 2019 08:00 ET | Source: Salarius Pharmaceuticals

Salarius Pharmaceuticals Hosting Key Opinion Leader Call on Epigenetics, The Regulatory System That Affects Gene Expression

HOUSTON, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that it will...
December 16, 2019 08:00 ET | Source: Salarius Pharmaceuticals

Salarius Pharmaceuticals Receives FDA Fast Track Designation for Lead Drug Candidate, Seclidemstat, in Relapsed or Refractory Ewing Sarcoma

HOUSTON, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced...

Next Page keyboard_arrow_right